<DOC>
	<DOCNO>NCT00246285</DOCNO>
	<brief_summary>The purpose study assess safety effectiveness risperidone ( antipsychotic medication ) adolescents schizophrenia 6 month treatment .</brief_summary>
	<brief_title>A Study Effectiveness Safety Risperidone Treatment Adolescents With Schizophrenia</brief_title>
	<detailed_description>Although safety effectiveness antipsychotic medication well-established adult schizophrenia , drug examine rigorously adolescent disorder . Preliminary experience suggest risperidone may hold promise treatment young subject . This open-label , multicenter trial risperidone , formulate oral solution tablet , treatment adolescent schizophrenia . It open-label , 6-month extension two previous double-blind study assess safety effectiveness risperidone treatment schizophrenia adolescent population . Patients may also enroll directly open-label trial . During first week study , patient receive increase dos risperidone reach optimal daily dose ( 2 6 mg/day ) , maintain throughout 6 month study . Assessments effectiveness include Positive Negative Syndrome Scale Schizophrenia ( PANSS ) , scale measuring symptom schizophrenia , Clinical Global Impression-Severity Illness subscale ( CGI-Severity ) , scale measure severity illness , Clinical Global Impression-Improvement subscale ( CGI-Improvement ) , scale measure clinical improvement , Children 's Global Assessment Scale . Safety evaluation include incidence adverse event throughout study , clinical laboratory test ( hematology , biochemistry , urinalysis ) , vital sign ( blood pressure , pulse , temperature ) , weight , electrocardiogram ( ECG ) recording specify interval . The study hypothesis risperidone effective treatment adolescent schizophrenia , well tolerate . Risperidone , oral solution ( 1 mg/ml ) daily ; dose increase 0.01 mg/kg body weight ( Day 1 ) range 2 6 mg/day 6 month . Oral tablet ( 0.5 , 1 , 2 , 3 , 4 mg ) daily ; dose increase 0.5 mg ( Day 1 ) range 2 6 mg/day 6 month .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Diagnosis schizophrenia criterion Diagnostic Statistical Manual Mental Diseases , 4th edition ( DSMIV ) expect benefit continuous treatment risperidone , include patient tolerate current antipsychotic therapy still exhibit symptom Positive Negative Syndrome Scale Schizophrenia ( PANSS ) score 40 120 start study ( required patient continue 2 previous study ) Meet criterion psychiatric disorder mental retardation ( document IQ &lt; 70 ) history substance dependence ( include alcohol , exclude nicotine caffeine ) hypersensitivity intolerance risperidone extrapyramidal symptom ( EPS ) tremor adequately control medication</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>antipsychotic agent</keyword>
	<keyword>risperidone</keyword>
	<keyword>adolescent</keyword>
</DOC>